|Elimination half-life||1 week|
|Duration of action||63.6 h|
|Excretion||Urine and faeces|
|Chemical and physical data|
|Molar mass||113.641 g·mol−1 4|
|3D model (JSmol)|
Semaglutide (USAN; trade name Ozempic) is a pharmaceutical drug developed by Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insulin. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016.
FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16–0 in favour. On December 5, 2017, semaglutide was approved by the US FDA. It can be used as both injection-type or oral-type drug. The marketing authorization in EU was granted on 8 February 2018. It is still under review by regulatory authorities in Japan, pending approval.
In humans semaglutide is chemically similar to glucagon-like peptide-1 (GLP-1). The only differences are two amino acid substitutions at positions 8 and 34, where 2-aminoisobutyric acid and arginine are present, respectively. In addition, lysine at position 26 is in its derivative form (acylated with stearic diacid).
Mechanism of action
- "Semaglutide Approval Status". drugs.com.
- "Novo Nordisk Files for Regulatory Approval of Once-Weekly Semaglutide with the FDA for the Treatment of Type 2 Diabetes" (Press release). Novo Nordisk. December 5, 2016.
- "Abstracts of the 48th EASD Annual Meeting of the European Association for the Study of Diabetes". Diabetologia. 55 (S1): 1–538. 2012. doi:10.1007/s00125-012-2688-9. PMID 22918257.
- Kalra, S; Gupta, Y (2015). "Once-weekly glucagon-like peptide 1 receptor agonists". The Journal of the Pakistan Medical Association. 65 (7): 796–798. PMID 26160096.
- "Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes". clinicaltrials.gov. U.S. National Library of Medicine. 25 September 2017. Retrieved 24 October 2017.
- Blundell, John; Finlayson, Graham; Axelsen, Mads; Flint, Anne; Gibbons, Catherine; Kvist, Trine; Hjerpsted, Julie B. (2017). "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity". Diabetes, Obesity and Metabolism. 19 (9): 1242–1251. doi:10.1111/dom.12932.
- "Drug can dramatically reduce weight of people with obesity". ScienceDaily. 23 October 2017. Retrieved 24 October 2017.
- "Development Status and FDA Approval Process for semaglutide". Drugs.com. 2017. Retrieved 24 October 2017.
- Davies, Melanie; Pieber, Thomas R.; Hartoft-Nielsen, Marie-Louise; Hansen, Oluf K. H.; Jabbour, Serge; Rosenstock, Julio (2017). "Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes". JAMA. 318 (15): 1460–1470. doi:10.1001/jama.2017.14752.
- "Novo Nordisk A/S: Ozempic® (semaglutide) approved in the EU for the treatment of type 2 diabetes". globenewswire.com. 9 February 2018. Retrieved 2018-08-19.
- Ozempic (semaglutide) approved in the US, https://www.novonordisk.com/media/news-details.2154210.html
- Lau, Jesper; Bloch, Paw; Schäffer, Lauge; Pettersson, Ingrid; Spetzler, Jane; Kofoed, Jacob; Madsen, Kjeld; Knudsen, Lotte Bjerre; et al. (2015). "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide". Journal of Medicinal Chemistry. 58 (18): 7370–7380. doi:10.1021/acs.jmedchem.5b00726. PMID 26308095.
- Gotfredsen, C. F.; Molck, A.-M.; Thorup, I.; Nyborg, N. C. B.; Salanti, Z.; Knudsen, L. B.; Larsen, M. O. (2014). "The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates" (PDF). Diabetes. 63 (7): 2486–2497. doi:10.2337/db13-1087. PMID 24608440.
- Marso, Steven P.; Bain, Stephen C.; Consoli, Agostino; Eliaschewitz, Freddy G.; Jódar, Esteban; Leiter, Lawrence A.; Lingvay, Ildiko; Rosenstock, Julio; Seufert, Jochen; Warren, Mark L.; Woo, Vincent; Hansen, Oluf; Holst, Anders G.; Pettersson, Jonas; Vilsbøll, Tina (2016). "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes". New England Journal of Medicine. 375 (19): 1834. doi:10.1056/NEJMoa1607141. PMID 27633186.